

# Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers

## Authors

---

Peter May,<sup>1</sup> Michael Rassner,<sup>2,3</sup> Marion Hoegner,<sup>1</sup> Wajma Shahbaz,<sup>4-7</sup> Ralph Wäsch,<sup>2,3</sup> Ana M. Gomez Martinez,<sup>1,8</sup> Burkhard Schmidt,<sup>9</sup> Sebastian Theurich,<sup>4-7</sup> Monika Engelhardt,<sup>2,3</sup> Florian Bassermann<sup>1,5-7,10</sup> and Johannes Jung<sup>1,5,6,8,11</sup>

<sup>1</sup>Department of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich;

<sup>2</sup>Department of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Freiburg; <sup>3</sup>Comprehensive Cancer Center Freiburg, Freiburg; <sup>4</sup>Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-University Munich, Munich; <sup>5</sup>Comprehensive Cancer Center Munich (CCCM), Munich; <sup>6</sup>German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg; <sup>7</sup>Bavarian Cancer Research Center (BZKF), Bavaria; <sup>8</sup>Center for Personalized Medicine, TUM University Hospital, Technical

University of Munich, Munich; <sup>9</sup>Hematology and Oncology Munich-Pasing Medical Care Center GmbH (MVZ), Munich; <sup>10</sup>Translatum, Center for Translational Cancer Research, Technical University of Munich, Munich and <sup>11</sup>Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany

Correspondence:

P. MAY - peter.may@tum.de

<https://doi.org/10.3324/haematol.2025.288320>

Received: June 24, 2025.

Accepted: October 9, 2025.

Early view: October 16, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

**Supplementary Table S1: Prior therapies and details of ixazomib maintenance.**



	N=44	(100.0%)
<b>Initial induction regimen</b>		
VCd	25	(56.8)
VRd	6	(13.6)
DaraVCd	5	(11.4)
DaraVRd	4	(9.1)
Other	4	(9.1)
<b>Prior therapy</b>		
Anti-CD38	17	(38.6)
Bortezomib	43	(97.7)
Cyclophosphamide	32	(72.7)
Lenalidomide	22	(50.0)
Carfilzomib	7	(15.9)
<b>Quantity of prior ASCTs</b>		
0	1	(2.3)
1	26	(59.1)
2 <sup>¶</sup>	17	(38.6)
<i>Tandem ASCT prior to Ixazomib maintenance</i>	10	(22.7)
<b>Prior lenalidomide maintenance</b>		
No lenalidomide maintenance	24	(54.5)
Yes (change from)	17	(38.6)
Yes (in the past)	3	(6.8)
<b>Duration of ixazomib maintenance</b>		
Median time of treatment (months) [range]	15.5 [1-71]	
Still on treatment (ongoing)	16	(36.4)
<b>Reason(s) for end of ixazomib treatment</b>		
Planned fixed duration of two years	9	(20.5)
Progression	15	(34.1)
Toxicity	2	(4.5)
Other	2	(4.5)
<b>Max. dose (mg)</b>		
4	23	(52.3)
3	19	(43.2)
2.3	2	(4.5)
<b>Dose reduction</b>		
Yes	17	(38.6)
No	27	(61.4)
<b>Reason(s) for dose reduction</b>		
Kidney function	8	(18.2)
Thrombocytopenia	6	(13.6)
Neutropenia	4	(9.1)
Gastrointestinal side effects	3	(6.8)
Polyneuropathy	1	(2.3)
Elevated transaminases	1	(2.3)

<sup>¶</sup>one patient had a total of three prior ASCTs. VCd=bortezomib, cyclophosphamide, dexamethasone; VRd=bortezomib, lenalidomide, dexamethasone; Dara=daratumumab; ASCT=autologous stem cell transplantation.

**Supplementary Table S2: Response assessment before and under ixazomib maintenance**

	N=44	(100.0%)
<b>Remission status before ixazomib maintenance</b>		
CR	23	(52.3)
VGPR	15	(34.1)
PR	4	(9.1)
SD	2	(4.5)
<b>Response<sup>†</sup></b>		
Deepened	6	(13.6)
Continuous CR	19	(43.2)
Continuous VGPR or PR	4	(9.1)
Progression	15	(34.1)
<b>Death</b>		
Total	5	(11.4)
Under ixazomib	0	(0.0)
MM-related	2	(4.5)
Other causes <sup>‡</sup>	3	(6.8)

<sup>†</sup>under ixazomib maintenance <sup>‡</sup>one patient died from COVID pneumonia, one from acute graft-versus-host disease after allogeneic stem cell transplantation and one from acute myeloid leukemia. CR=complete remission; VGPR=very good partial remission; PR=partial remission; SD=stable disease.

**A****B**

**Supplementary Figure S1: Patient-specific treatment and response assessment.** (A) Sankey diagram illustrating patient-level response transitions from beginning to end of ixazomib maintenance therapy. (B) Swimmer plot of treatment duration (dark line) and PFS (blue bar) for each patient. Patients are ordered and grouped by cytogenetic risk status (Standard Risk, High Risk, n.a.). Symbols indicate patient status at data cutoff or time of event: ongoing (green circle) or death (red cross). CR=complete remission; VGPR=very good partial remission; PR=partial remission; SD=stable disease; PD=progressive disease; PFS=progression-free survival; n.a.=not available.